Dualitas Therapeutics has announced a research collaboration and licence agreement with Roche to discover and develop novel bispecific antibody (BsAb) therapies for immunology and inflammation (I&I) diseases. The DualScreenTM platform is designed to support high-throughput discovery of bispecific antibodies based on proximity biology. Unlike conventional approaches that typically begin with selected target pairs, the platform evaluates a broad range of targets and epitopes